Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy

Por Durrant, L G, Noble, P, Spendlove, I
Publicado em 2012

CD55 is over-expressed in the tumour environment

Por Li, L, Spendlove, I, Morgan, J, Durrant, L G
Publicado em 2001

Characterization of a human X mouse T cell hybridoma and identification of a clone secreting and binding interleukin-2.

Por Durrant, L G, Parkar, M, Kenworthy, N, Taylor, G M
Publicado em 1984

Co-stimulation of gastrointestinal tumour cell growth by gastrin, transforming growth factor alpha and insulin like growth factor-I.

Por Durrant, L. G., Watson, S. A., Hall, A., Morris, D. L.
Publicado em 1991

Hormonal control of gastric and colorectal cancer in man.

Por Morris, D L, Watson, S A, Durrant, L G, Harrison, J D
Publicado em 1989

Development of an ELISA to detect early local relapse of colorectal cancer.

Por Durrant, L. G., Jones, H., Armitage, N. C., Baldwin, R. W.
Publicado em 1989

Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy

Por Shehata, M, Mukherjee, A, Deen, S, Al-Attar, A, Durrant, L G, Chan, S
Publicado em 2009

Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36.

Por Austin, E B, Robins, R A, Durrant, L G, Price, M R, Baldwin, R W
Publicado em 1989

The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer

Por Popple, A, Durrant, L G, Spendlove, I, Rolland, P, Scott, I V, Deen, S, Ramage, J M
Publicado em 2012

Enhanced recognition of human colorectal tumour cells using combinations of monoclonal antibodies.

Por Durrant, L. G., Robins, R. A., Ballantyne, K. C., Marksman, R. A., Hardcastle, J. D., Baldwin, R. W.
Publicado em 1989

Quantitation of MHC antigen expression on colorectal tumours and its association with tumour progression.

Por Durrant, L. G., Ballantyne, K. C., Armitage, N. C., Robins, R. A., Marksman, R., Hardcastle, J. D., Baldwin, R. W.
Publicado em 1987

Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients.

Por Durrant, L G, Byers, V S, Scannon, P J, Rodvien, R, Grant, K, Robins, R A, Marksman, R A, Baldwin, R W
Publicado em 1989

Antigenicity of newly established colorectal carcinoma cell lines.

Por Durrant, L. G., Robins, R. A., Pimm, M. V., Perkins, A. C., Armitage, N. C., Hardcastle, J. D., Baldwin, R. W.
Publicado em 1986

Sensitivity of newly established colorectal cell lines to cytotoxic drugs and monoclonal antibody drug conjugates.

Por Durrant, L. G., Garnett, M. C., Gallego, J., Armitage, N. C., Ballantyne, K. C., Marksman, R. A., Hardcastle, J. D., Baldwin, R. W.
Publicado em 1987

Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma

Por Pritchard-Jones, K, Spendlove, I, Wilton, C, Whelan, J, Weeden, S, Lewis, I, Hale, J, Douglas, C, Pagonis, C, Campbell, B, Alvarez, P, Halbert, G, Durrant, L G
Publicado em 2005

Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer

Por Maxwell-Armstrong, C A, Durrant, L G, Buckley, T J D, Scholefield, J H, Robins, R A, Fielding, K, Monson, J R T, Guillou, P, Calvert, H, Carmichael, J, Hardcastle, J D
Publicado em 2001